Results 131 to 140 of about 206,446 (295)

Association of angiotensin-converting enzyme insertion/deletion (ACE I/D) gene polymorphism with susceptibility to prostate cancer: an updated meta-analysis [PDF]

, 2022
Jianhui Du, Jianhua Lan, Hai Yang, Qiao Ying, Guohua Huang, Jian Mou, Long Jia, Zhenghua Qiao, Qiyi Hu   +8 more
openalex   +1 more source

In Vitro and In Silico Studies on Angiotensin I-Converting Enzyme Inhibitory Peptides Found in Hydrophobic Domains of Porcine Elastin. [PDF]

Molecules, 2023
Hatakenaka T, Kato T, Okamoto K.
europepmc   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Angiotensin I-Converting Enzyme [PDF]

The Journal of Molecular Diagnostics, 2000
Domnita Crisan, Jeanne Carr
openaire   +1 more source

Purification and Molecular Docking Study on the Angiotensin I-Converting Enzyme (ACE)-Inhibitory Peptide Isolated from Hydrolysates of the Deep-Sea Mussel Gigantidas vrijenhoeki. [PDF]

Mar Drugs, 2023
Heo SY, Kang N, Kim EA, Kim J, Lee SH, Ahn G, Oh JH, Shin AY, Kim D, Heo SJ.   +9 more
europepmc   +1 more source

Left ventricular function improvement during angiotensin receptor–neprilysin inhibitor treatment in a cohort of HFrEF/HFmrEF patients

ESC Heart Failure, Volume 12, Issue 2, Page 1151-1165, April 2025.
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller, Tobias Harm, Manuel Sigle, Parwez Aidery, Klaus‐Peter Kreisselmeier, Livia Baas, Andreas Goldschmied, Meinrad Paul Gawaz, Karin Anne Lydia Müller   +8 more
wiley   +1 more source

Role of the vasodilator peptide angiotensin-(1–7) in cardiovascular drug therapy

Vascular Health and Risk Management, 2007
Christoph Schindler1, Peter Bramlage1, Wilhelm Kirch1, Carlos M Ferrario21Institute of Clinical Pharmacology, Medical Faculty, Technical University of Dresden, Dresden, Germany; 2Hypertension and Vascular Disease Center, Wake Forest University, School of
Christoph Schindler, Peter Bramlage, Wilhelm Kirch, Carlos M Ferrario   +3 more
doaj  

Mechanoactivation of the angiotensin II type 1 receptor induces β‐arrestin‐biased signaling through Gα_icoupling

, 2017
Jialu Wang, Kenji Hanada, Clarice Gareri, Howard A. Rockman   +3 more
openalex   +2 more sources

Preparation and activity evaluation of angiotensin-I converting enzyme inhibitory peptides from protein hydrolysate of mulberry leaf. [PDF]

Front Nutr, 2022
Chen Y, Zhang Y, Qi Q, Liang F, Wang N, Chen Q, Li X, Sun S, Wang X, Bai K, Wang W, Jiao Y.   +11 more
europepmc   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source